Kidney Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Pharmacologic Class, By Country, And Segment Forecasts, 2016 - 2022
This report can be delivered to the clients within 48 hours
The global kidney cancer drugs market size is expected to be valued at USD 6.3 billion by 2022, as per a new report by Grand View Research, Inc., registering a CAGR of 5.4% during the forecast period. Market growth is largely driven by factors such as availability of novel drugs and presence of a strong pipeline. Growth can also be attributed to rise in incidence of renal cancer due to growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol.
In 2012, kidney cancer was the 13th most prevalent cancer worldwide, accounting for approximately 2.0% of all adult malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor.
Further key findings from the report suggest:
The global kidney cancer drugs market size is expected to be valued at USD 6.3 billion by 2022, as per a new report by Grand View Research, Inc., registering a CAGR of 5.4% during the forecast period. Market growth is largely driven by factors such as availability of novel drugs and presence of a strong pipeline. Growth can also be attributed to rise in incidence of renal cancer due to growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol.
In 2012, kidney cancer was the 13th most prevalent cancer worldwide, accounting for approximately 2.0% of all adult malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor.
Further key findings from the report suggest:
- Increasing incidence of the disease and rising geriatric population globally are amongst major factors stimulating market growth
- Novel agents have expanded market opportunities through larger number of patients under treatment and better treatment prospects compared to traditional therapies. The notable clinical profile of immuno-oncology drugs is reflected their rapid uptake and expansion of indications
- The current treatment landscape in metastatic and advanced RCC will shift from TKI and mTOR inhibitors to specific immuno-oncology agents like immune checkpoint inhibitors (ICI), which have demonstrated positive results on PFS as monotherapy (Opdivo) or combination therapy (Opdivo+Yervoy)
- U.S. accounted for more than 35.0% of the market in 2016 due to increasing incidence of renal cell carcinoma and presence of key manufacturers in the country. On the other hand, surge in kidney cancer screening is a key driver in markets such as EU
- Emerging markets in Asia Pacific and Middle East and Africa are fueled by increasing expenditure on healthcare, a large untapped patient population base due to rise in elderly population, and improvement in diagnostic technologies
- Some of the key players operating in this market are Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional expansion in emerging markets are key strategic undertakings of these companies to increase market share.
CHAPTER 1 RESEARCH METHODOLOGY
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer
3.2. Epidemiology
CHAPTER 4 GLOBAL MARKET OVERVIEW
4.1 Market by Therapeutic Class
4.2 Market Size and Forecast 2016 - 2022
4.3 Market Share Distribution, by Company 2016 - 2022
4.4 Sales Performance, by Pharmacologic Class
4.5 Market Dynamics and Brand Strategies
4.6 Patent Expiry Analysis
4.7 Kidney Cancer Drugs Market: Drivers and Restraints
4.7.1 Drivers
4.7.2 Challenges
4.8 M&A, Deal Landscape (2013 - 2017 YTD)
4.8.1 Mergers & Acquisitions
4.8.2 Deals Landscape
4.9 Evolution of Biosimilars
4.10 Emerging Markets
4.11 Reimbursement Scenario
4.12 Kidney Cancer Sector SWOT
CHAPTER 5 PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Pfizer
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Sales Forecast Through 2022
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.4.2 Catalysts & Events Calendar
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Novartis
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Bayer
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Genentech
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.4.2 Catalysts & Events Calendar
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Bristol-Myers Squibb
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2022
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.4.2 Catalysts & Events Calendar
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
6.6 Exelixis
6.6.1 Company Overview
6.6.2 Current Product Portfolio
6.6.3 Product Forecast Sales Through 2022
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.4.2 Catalysts & Events Calendar
6.6.5 Pipeline Analysis & Overview
6.6.6 SWOT
6.7 Eisai
6.7.1 Company Overview
6.7.2 Current Product Portfolio
6.7.3 Product Forecast Sales Through 2022
6.7.4 Strategic Initiatives
6.7.4.1 Key Company News Flow
6.7.5 Pipeline Analysis & Overview
6.7.6 SWOT
6.8 Prometheus Labs
6.8.1 Company Overview
6.8.2 Current Product Portfolio
6.8.3 Product Forecast Sales Through 2022
6.8.4 Strategic Initiatives
6.8.4.1 Key Company News Flow
6.8.5 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer
3.2. Epidemiology
CHAPTER 4 GLOBAL MARKET OVERVIEW
4.1 Market by Therapeutic Class
4.2 Market Size and Forecast 2016 - 2022
4.3 Market Share Distribution, by Company 2016 - 2022
4.4 Sales Performance, by Pharmacologic Class
4.5 Market Dynamics and Brand Strategies
4.6 Patent Expiry Analysis
4.7 Kidney Cancer Drugs Market: Drivers and Restraints
4.7.1 Drivers
4.7.2 Challenges
4.8 M&A, Deal Landscape (2013 - 2017 YTD)
4.8.1 Mergers & Acquisitions
4.8.2 Deals Landscape
4.9 Evolution of Biosimilars
4.10 Emerging Markets
4.11 Reimbursement Scenario
4.12 Kidney Cancer Sector SWOT
CHAPTER 5 PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Pfizer
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Sales Forecast Through 2022
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.4.2 Catalysts & Events Calendar
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Novartis
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Bayer
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Genentech
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.4.2 Catalysts & Events Calendar
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Bristol-Myers Squibb
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2022
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.4.2 Catalysts & Events Calendar
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
6.6 Exelixis
6.6.1 Company Overview
6.6.2 Current Product Portfolio
6.6.3 Product Forecast Sales Through 2022
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.4.2 Catalysts & Events Calendar
6.6.5 Pipeline Analysis & Overview
6.6.6 SWOT
6.7 Eisai
6.7.1 Company Overview
6.7.2 Current Product Portfolio
6.7.3 Product Forecast Sales Through 2022
6.7.4 Strategic Initiatives
6.7.4.1 Key Company News Flow
6.7.5 Pipeline Analysis & Overview
6.7.6 SWOT
6.8 Prometheus Labs
6.8.1 Company Overview
6.8.2 Current Product Portfolio
6.8.3 Product Forecast Sales Through 2022
6.8.4 Strategic Initiatives
6.8.4.1 Key Company News Flow
6.8.5 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
LIST OF TABLES
Table 1 Incidence Rate per 100,000 in Seven Major Markets
Table 2 Incidence Rate per 100,000 in Forecast, Spain
Table 3 Marketed Drugs for Kidney Cancer
Table 4 Marketed Drugs for Kidney Cancer
Table 5 Sales Performance by Therapeutic Class, 2016 -
Table 6 Sales Performance by Market, in USD million, 2016 -
Table 7 Sales Performance by Market, by Pharmacologic Class, 2016 -
Table 8 Sales Performance by Pharmacologic Class, 2016 -
Table 9 U.S. Patents for Current Kidney Cancer Drugs
Table 10 Avastin (bevacizumab) Biosimilars Across Various Indications
Table 11 R&D Pipeline Overview
Table 12 Late Stage Pipeline
Table 13 Bavencio
Table 14 Tecentriq
Table 15 Fotivda
Table 16 Epacadostat
Table 17 Rocapuldencel-T
Table 18 Pipeline Forecast
Table 19 Pfizer Sales Forecast, 2016 - 2022
Table 20 Pfizer Pipeline
Table 21 Novartis Sales Forecast, 2016 - 2022
Table 22 Bayer Sales Forecast, 2016 - 2022
Table 23 Bayer Pipeline
Table 24 Genentech (Roche) Sales Forecast, 2016 - 2022
Table 25 Genentech (Roche) Pipeline
Table 26 Bristol-Myers Squibb Sales Forecast, 2016 - 2022
Table 27 Bristol-Myers Squibb Pipeline
Table 28 Exelixis Sales Forecast, 2016 - 2022
Table 29 Exelixis Pipeline
Table 30 Eisai Sales Forecast, 2016 - 2022
Table 31 Prometheus Labs Sales Forecast, 2016 - 2022LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Race and Gender Specific Prevalence of RCC in the U.S.
Fig. 8 Gender Specific Incidence Rate per 100,000 in the U.K. (1993 - 2014)
Fig. 9 Kidney Cancer Drugs Market Share, by Therapeutic Class, 2016 -
Fig. 10 Regional Market Size, 2016 - 2022
Fig. 11 Market Shares Distribution, 2016 - 2022
Fig. 12 Sales by Pharmacologic Class, 2016 - 2022
Fig. 13 Kidney Cancer SWOT
Fig. 14 Pfizer SWOT Analysis
Fig. 15 Novartis SWOT Analysis
Fig. 16 Bayer SWOT Analysis
Fig. 17 Genentech SWOT Analysis
Fig. 18 Bristol-Myers Squibb SWOT Analysis
Fig. 19 Exelixis SWOT Analysis
Fig. 20 Eisai SWOT Analysis
Fig. 21 Prometheus Labs SWOT Analysis
Table 1 Incidence Rate per 100,000 in Seven Major Markets
Table 2 Incidence Rate per 100,000 in Forecast, Spain
Table 3 Marketed Drugs for Kidney Cancer
Table 4 Marketed Drugs for Kidney Cancer
Table 5 Sales Performance by Therapeutic Class, 2016 -
Table 6 Sales Performance by Market, in USD million, 2016 -
Table 7 Sales Performance by Market, by Pharmacologic Class, 2016 -
Table 8 Sales Performance by Pharmacologic Class, 2016 -
Table 9 U.S. Patents for Current Kidney Cancer Drugs
Table 10 Avastin (bevacizumab) Biosimilars Across Various Indications
Table 11 R&D Pipeline Overview
Table 12 Late Stage Pipeline
Table 13 Bavencio
Table 14 Tecentriq
Table 15 Fotivda
Table 16 Epacadostat
Table 17 Rocapuldencel-T
Table 18 Pipeline Forecast
Table 19 Pfizer Sales Forecast, 2016 - 2022
Table 20 Pfizer Pipeline
Table 21 Novartis Sales Forecast, 2016 - 2022
Table 22 Bayer Sales Forecast, 2016 - 2022
Table 23 Bayer Pipeline
Table 24 Genentech (Roche) Sales Forecast, 2016 - 2022
Table 25 Genentech (Roche) Pipeline
Table 26 Bristol-Myers Squibb Sales Forecast, 2016 - 2022
Table 27 Bristol-Myers Squibb Pipeline
Table 28 Exelixis Sales Forecast, 2016 - 2022
Table 29 Exelixis Pipeline
Table 30 Eisai Sales Forecast, 2016 - 2022
Table 31 Prometheus Labs Sales Forecast, 2016 - 2022LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Race and Gender Specific Prevalence of RCC in the U.S.
Fig. 8 Gender Specific Incidence Rate per 100,000 in the U.K. (1993 - 2014)
Fig. 9 Kidney Cancer Drugs Market Share, by Therapeutic Class, 2016 -
Fig. 10 Regional Market Size, 2016 - 2022
Fig. 11 Market Shares Distribution, 2016 - 2022
Fig. 12 Sales by Pharmacologic Class, 2016 - 2022
Fig. 13 Kidney Cancer SWOT
Fig. 14 Pfizer SWOT Analysis
Fig. 15 Novartis SWOT Analysis
Fig. 16 Bayer SWOT Analysis
Fig. 17 Genentech SWOT Analysis
Fig. 18 Bristol-Myers Squibb SWOT Analysis
Fig. 19 Exelixis SWOT Analysis
Fig. 20 Eisai SWOT Analysis
Fig. 21 Prometheus Labs SWOT Analysis
